Mikkel Bring Christensen

List of Publications by Year
in descending order

114 papers	4,609 citations	126907 33 h-index	110387 64 g-index
120 all docs	120 docs citations	120 times ranked	4760 citing authors

#	Article	IF	Citations
1	Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ: British Medical Journal, 2012, 344, d7771-d7771.	2.3	731
2	Glucose-Dependent Insulinotropic Polypeptide. Diabetes, 2011, 60, 3103-3109.	0.6	265
3	Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies. Diabetologia, 2013, 56, 965-972.	6.3	199
4	Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. PLoS ONE, 2016, 11, e0166125.	2.5	188
5	Medication review in hospitalised patients to reduce morbidity and mortality. The Cochrane Library, 2016, 2016, CD008986.	2.8	179
6	Evidence of Extrapancreatic Glucagon Secretion in Man. Diabetes, 2016, 65, 585-597.	0.6	136
7	Regulation of glucagon secretion by incretins. Diabetes, Obesity and Metabolism, 2011, 13, 89-94.	4.4	132
8	Secretion of Glucose-Dependent Insulinotropic Polypeptide in Patients With Type 2 Diabetes. Diabetes Care, 2013, 36, 3346-3352.	8.6	125
9	Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals. Diabetes, 2019, 68, 906-917.	0.6	118
10	Specificity and sensitivity of commercially available assays for glucagon and oxyntomodulin measurement in humans. European Journal of Endocrinology, 2014, 170, 529-538.	3.7	116
11	Glucose-Dependent Insulinotropic Polypeptide Inhibits Bone Resorption in Humans. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E2325-E2329.	3.6	104
12	Glucagon and Type 2 Diabetes: the Return of the Alpha Cell. Current Diabetes Reports, 2014, 14, 555.	4.2	96
13	Speciesâ€specific action of (Pro3)GIP â€“ a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors. British Journal of Pharmacology, 2016, 173, 27-38.	5.4	86
14	Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study. Diabetologia, 2019, 62, 665-675.	6.3	81
15	Glucose-dependent Insulinotropic Polypeptide: Blood Glucose Stabilizing Effects in Patients With Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E418-E426.	3.6	79
16	Nâ€terminally and Câ€terminally truncated forms of glucoseâ€dependent insulinotropic polypeptide are highâ€affinity competitive antagonists of the human GIP receptor. British Journal of Pharmacology, 2016, 173, 826-838.	5.4	72
17	Lixisenatide for type 2 diabetes mellitus. Expert Opinion on Investigational Drugs, 2011, 20, 549-557.	4.1	70
18	GIP(3-30)NH2 is an efficacious GIP receptor antagonist in humans: a randomised, double-blinded, placebo-controlled, crossover study. Diabetologia, 2018, 61, 413-423.	6.3	66

#	Article	IF	Citations
19	Medication review in hospitalised patients to reduce morbidity and mortality. , 2013, , CD008986.		64
20	Glucose-Dependent Insulinotropic Polypeptide (GIP) Inhibits Bone Resorption Independently of Insulin and Glycemia. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 288-294.	3.6	64
21	Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists. Peptides, 2020, 125, 170183.	2.4	61
22	Glucose-Dependent Insulinotropic Polypeptide Augments Glucagon Responses to Hypoglycemia in Type 1 Diabetes. Diabetes, 2015, 64, 72-78.	0.6	60
23	Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents. Peptides, 2018, 100, 173-181.	2.4	56
24	Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity. Expert Opinion on Emerging Drugs, 2021, 26, 231-243.	2.4	51
25	GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 17-29.	3.3	49
26	The Alpha-Cell as Target for Type 2 Diabetes Therapy. Review of Diabetic Studies, 2011, 8, 369-381.	1.3	49
27	The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretionâ€"A Review. International Journal of Molecular Sciences, 2019, 20, 4092.	4.1	47
28	Hemodynamic Effects of Glucagon: A Literature Review. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1804-1812.	3.6	43
29	Once-Weekly GLP-1 Agonists: How Do They Differ from Exenatide and Liraglutide?. Current Diabetes Reports, 2010, 10, 124-132.	4.2	42
30	Transfer of liraglutide from blood to cerebrospinal fluid is minimal in patients with type 2 diabetes. International Journal of Obesity, 2015, 39, 1651-1654.	3.4	41
31	Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men Without Diabetes. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2953-2960.	3.6	41
32	Hypoglycaemia when adding sulphonylurea to metformin: a systematic review and network metaâ€analysis. British Journal of Clinical Pharmacology, 2016, 82, 1291-1302.	2.4	39
33	No Acute Effects of Exogenous Glucose-Dependent Insulinotropic Polypeptide on Energy Intake, Appetite, or Energy Expenditure When Added to Treatment With a Long-Acting Glucagon-Like Peptide 1 Receptor Agonist in Men With Type 2 Diabetes. Diabetes Care, 2020, 43, 588-596.	8.6	38
34	Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2013, 6, 217.	2.4	37
35	GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e725-e738.	3.6	37
36	Elimination and Degradation of Glucagon-like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide in Patients with End-Stage Renal Disease. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 2457-2466.	3.6	31

#	Article	IF	Citations
37	Searching for the physiological role of glucoseâ€dependent insulinotropic polypeptide. Journal of Diabetes Investigation, 2016, 7, 8-12.	2.4	30
38	Polypharmacy and medication deprescribing: A survey among multimorbid older adults in Denmark. Pharmacology Research and Perspectives, 2018, 6, e00431.	2.4	30
39	Long term treatment with stimulant laxatives â€“ clinical evidence for effectiveness and safety?. Scandinavian Journal of Gastroenterology, 2019, 54, 27-34.	1.5	28
40	Glucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease. Peptides, 2020, 125, 170174.	2.4	27
41	An overview of obesity mechanisms in humans: Endocrine regulation of food intake, eating behaviour and common determinants of body weight. Diabetes, Obesity and Metabolism, 2021, 23, 17-35.	4.4	27
42	Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. IDrugs: the Investigational Drugs Journal, 2009, 12, 503-13.	0.7	26
43	A Systematic Review on Insulin Overdose Cases: Clinical Course, Complications and Treatment Options. Basic and Clinical Pharmacology and Toxicology, 2018, 122, 650-659.	2.5	25
44	GIP and the gut-bone axis â€“ Physiological, pathophysiological and potential therapeutic implications. Peptides, 2020, 125, 170197.	2.4	25
45	The role of endogenous GIP and GLP-1 in postprandial bone homeostasis. Bone, 2020, 140, 115553.	2.9	25
46	Medication-related experiences of patients with polypharmacy: a systematic review of qualitative studies. BMJ Open, 2020, 10, e036158.	1.9	25
47	Cholecystokinin-Induced Gallbladder Emptying and Metformin Elicit Additive Glucagon-Like Peptide-1 Responses. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2076-2083.	3.6	24
48	The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus. Expert Opinion on Drug Discovery, 2014, 9, 1223-1251.	5.0	23
49	Quality of care for people with multimorbidity â€“ a case series. BMC Health Services Research, 2017, 17, 745.	2.2	22
50	Determinants of Fasting Hyperglucagonemia in Patients with Type 2 Diabetes and Nondiabetic Control Subjects. Metabolic Syndrome and Related Disorders, 2018, 16, 530-536.	1.3	22
51	Identification and Metabolic Profiling of a Novel Human Gut-derived LEAP2 Fragment. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e966-e981.	3.6	22
52	Adverse effects associated with high-dose olanzapine therapy in patients admitted to inpatient psychiatric care. Clinical Toxicology, 2014, 52, 39-43.	1.9	21
53	Effect of a medicines management model on medicationâ€related readmissions in older patients admitted to a medical acute admission unitâ€”A randomized controlled trial. Journal of Evaluation in Clinical Practice, 2019, 25, 88-96.	1.8	21
54	Effects of endogenous GIP in patients with type 2 diabetes. European Journal of Endocrinology, 2021, 185, 33-45.	3.7	21

#	Article	IF	Citations
55	LEAP2 reduces postprandial glucose excursions and ad libitum food intake in healthy men. Cell Reports Medicine, 2022, 3, 100582.	6.5	21
56	GIPâ€™s effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3â€“30)NH2. Bone, 2020, 130, 115079.	2.9	20
57	Arginine-vasopressin mediates counter-regulatory glucagon release and is diminished in type 1 diabetes. ELife, 2021, 10, .	6.0	20
58	Glucagon-like peptide-2, but not glucose-dependent insulinotropic polypeptide, stimulates glucagon release in patients with type 1 diabetes. Regulatory Peptides, 2010, 163, 96-101.	1.9	18
59	Clinical Pharmacokinetics and Pharmacodynamics of Albiglutide. Clinical Pharmacokinetics, 2017, 56, 719-731.	3.5	18
60	GIPâ€™s involvement in the pathophysiology of type 2 diabetes. Peptides, 2020, 125, 170178.	2.4	18
61	Total burden of disease in cancer patients at diagnosisâ€”a Danish nationwide study of multimorbidity and redeemed medication. British Journal of Cancer, 2020, 123, 1033-1040.	6.4	17
62	Highâ€Dose Glucagon Has Hemodynamic Effects Regardless of Cardiac Betaâ€Adrenoceptor Blockade: A Randomized Clinical Trial. Journal of the American Heart Association, 2020, 9, e016828.	3.7	15
63	Exendin(9â€39)<scp>NH₂</scp>: Recommendations for clinical use based on a systematic literature review. Diabetes, Obesity and Metabolism, 2021, 23, 2419-2436.	4.4	15
64	Doseâ€dependent efficacy of the glucoseâ€dependent insulinotropic polypeptide (<scp>GIP</scp> receptor antagonist <scp>GIP</scp>(3â€30)<scp>NH₂</scp> on <scp>GIP</scp> actions in humans. Diabetes, Obesity and Metabolism, 2021, 23, 68-74.	4.4	14
65	Albiglutide for treating type 2 diabetes: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 1493-1503.	3.3	13
66	General Practitionersâ€™ Barriers Toward Medication Reviews in Polymedicated Multimorbid Patients. Health Services Research and Managerial Epidemiology, 2018, 5, 233339281879216.	0.9	13
67	The unobtainable placebo: control of independent clinical research by industry?. Lancet, The, 2012, 379, 30.	13.7	12
68	Higher Endogenous Glucose Production During OGTT vs Isoglycemic Intravenous Glucose Infusion. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4377-4384.	3.6	12
69	Glucose-Dependent Insulinotropic Polypeptide Is a Pancreatic Polypeptide Secretagogue in Humans. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e502-e510.	3.6	12
70	Glucose-Dependent Insulinotropic Polypeptide (GIP) Reduces Bone Resorption in Patients With Type 2 Diabetes. Journal of the Endocrine Society, 2020, 4, bvaa097.	0.2	12
71	Acute hypoglycemia and risk of cardiac arrhythmias in insulin-treated type 2 diabetes and controls. European Journal of Endocrinology, 2021, 185, 343-353.	3.7	12
72	Glucagon-like peptide-1 receptor regulation of basal dopamine transporter activity is species-dependent. Neurochemistry International, 2020, 138, 104772.	3.8	11

#	Article	IF	Citations
73	Overdoses with Aripiprazole: Signs, Symptoms and Outcome in 239 Exposures Reported to the Danish Poison Information Centre. Basic and Clinical Pharmacology and Toxicology, 2018, 122, 293-298.	2.5	10
74	Clinical pharmacology of imeglimin for the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy, 2020, 21, 871-882.	1.8	10
75	Causes of discrepancies between medications listed in the national electronic prescribing system and patients' actual use of medications. Basic and Clinical Pharmacology and Toxicology, 2021, 129, 221-231.	2.5	10
76	64-OR: Postprandial Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide in Type 2 Diabetes. Diabetes, 2019, 68, .	0.6	10
77	Effects of a comprehensive medication review intervention on healthâ€related quality of life and other clinical outcomes in geriatric outpatients with polypharmacy: A pragmatic randomized clinical trial. British Journal of Clinical Pharmacology, 2022, 88, 3360-3369.	2.4	10
78	Important Aspects of Pharmacistâ€led Medication Reviews in an Acute Medical Ward. Basic and Clinical Pharmacology and Toxicology, 2018, 122, 253-261.	2.5	9
79	Preclinical discovery and development of colesevelam for the treatment of type 2 diabetes. Expert Opinion on Drug Discovery, 2018, 13, 1161-1167.	5.0	9
80	Two-bag intravenous N-acetylcysteine, antihistamine pretreatment and high plasma paracetamol levels are associated with a lower incidence of anaphylactoid reactions to N-acetylcysteine. Clinical Toxicology, 2020, 58, 698-704.	1.9	9
81	Therapy for Obesity Based on Gastrointestinal Hormones. Review of Diabetic Studies, 2011, 8, 339-347.	1.3	9
82	Outcomes following calcium channel blocker exposures reported to a poison information center. BMC Pharmacology & Toxicology, 2018, 19, 78.	2.4	8
83	Low-dose aspirin for primary and secondary prevention of cardiovascular events in Denmark 1998â€“2018. Scientific Reports, 2021, 11, 13603.	3.3	8
84	GIP(3-30)NH2 â€“ a tool for the study of GIP physiology. Current Opinion in Pharmacology, 2020, 55, 31-40.	3.5	8
85	Glycemic control and use of glucose-lowering medications in hospital-admitted type 2 diabetes patients over 80 years. Scientific Reports, 2020, 10, 4095.	3.3	6
86	What is on the horizon for type 2 diabetes pharmacotherapy? â€“ An overview of the antidiabetic drug development pipeline. Expert Opinion on Drug Discovery, 2020, 15, 1253-1265.	5.0	6
87	Glucagon Clearance Is Preserved in Type 2 Diabetes. Diabetes, 2022, 71, 73-82.	0.6	6
88	The GetGoal clinical trial program of lixisenatide, a once-daily GLP-1 receptor agonist. Expert Review of Endocrinology and Metabolism, 2011, 6, 513-525.	2.4	5
89	Acute concomitant glucoseâ€dependent insulinotropic polypeptide receptor antagonism during glucagonâ€like peptide 1 receptor agonism does not affect appetite, resting energy expenditure or food intake in patients with type 2 diabetes and overweight/obesity. Diabetes, Obesity and Metabolism, 2022, 24, 1882-1887.	4.4	5
90	Shortâ€term mortality following tramadol poisonings in Denmark. Basic and Clinical Pharmacology and Toxicology, 2022, 131, 83-92.	2.5	5

#	Article	IF	Citations
91	The effects of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: protocol for a systematic review with meta-analysis of randomised trials. BMJ Open, 2014, 4, e005378-e005378.	1.9	4
92	The effect of 6-day subcutaneous glucose-dependent insulinotropic polypeptide infusion on time in glycaemic range in patients with type 1 diabetes: a randomised, double-blind, placebo-controlled crossover trial. Diabetologia, 2021, 64, 2425-2431.	6.3	4
93	Glucoseâ€dependent insulinotropic polypeptide induces lipolysis during stable basal insulin substitution and hyperglycaemia in men with type 1 diabetes: A randomized, doubleâ€blind, placeboâ€controlled, crossover clinical trial. Diabetes, Obesity and Metabolism, 2022, 24, 142-147.	4.4	4
94	Mono- and Co-Activation of the GIP and GLP-1 Receptors Inhibits Bone Resorption. Diabetes, 2018, 67, .	0.6	4
95	Dulaglutide: a novel once-weekly glucagon-like peptide-1 receptor agonist. Clinical Investigation, 2014, 4, 729-743.	0.0	3
96	Effects of high-dose, intravenous lipid emulsion on laboratory tests in humans: a randomized, placebo-controlled, double-blind, clinical crossover trial. Clinical Chemistry and Laboratory Medicine, 2018, 56, 2047-2057.	2.3	3
97	Hemodynamic Effects of Intravenous, Highâ€Dose Lipid Emulsion With and Without Metoprolol Infusion in Healthy Volunteers: A Randomized Clinical Trial. Clinical Pharmacology and Therapeutics, 2019, 105, 1009-1017.	4.7	3
98	Postprandial Effects of Individual and Combined GIP and GLP-1 Receptor Antagonization in Healthy Subjects. Diabetes, 2018, 67, 145-OR.	0.6	3
99	89-LB: The Effect of GIP on Plasma Glucose in a Setting of Prandial Insulin Overdose and Physical Activity after Meal Intake in Patients with Type 1 Diabetes. Diabetes, 2020, 69, .	0.6	3
100	Acute changes in plasma glucose increases left ventricular systolic function in insulinâ€treated patients with type 2 diabetes and controls. Diabetes, Obesity and Metabolism, 2022, 24, 1123-1131.	4.4	3
101	Comment on: Gogebakan et al. Glucose-Dependent Insulinotropic Polypeptide Reduces Fat-Specific Expression and Activity of 11Â-Hydroxysteroid Dehydrogenase Type 1 and Inhibits Release of Free Fatty Acids. Diabetes 2012;61:292-300. Diabetes, 2012, 61, e12-e12.	0.6	1
102	An alternative combination therapy for type 2 diabetes?. Lancet, The, 2015, 385, 2020-2022.	13.7	1
103	Effects of glucose-dependent insulinotropic polypeptide on glucagon. Cardiovascular Endocrinology, 2016, 5, 75-81.	0.8	1
104	Pancreatic polypeptide: A potential biomarker of glucoseâ€dependent insulinotropic polypeptide receptor activation in vivo. Diabetic Medicine, 2021, 38, e14592.	2.3	1
105	Endogenous Glucose-Dependent Insulinotropic Polypeptide Contributes to Sitagliptin-Mediated Improvement in Beta Cell Function in Patients with Type 2 Diabetes. Diabetes, 0, , .	0.6	1
106	Prehospital evaluation of patients with chronic obstructive pulmonary disease. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine, 2009, 17, P10.	2.6	0
107	Add-on to metformin in T2DMâ€”linagliptin or glimepiride?. Nature Reviews Endocrinology, 2012, 8, 576-578.	9.6	0
108	Authors' reply to de Oliveira and Iverson. BMJ: British Medical Journal, 2012, 344, e1459-e1459.	2.3	0

#	Article	IF	Citations
109	Response to Letter to the Editor: â€œHemodynamic Effects of Glucagon: A Literature Reviewâ€• Journal of Clinical Endocrinology and Metabolism, 2018, 103, 4480-4481.	3.6	0
110	THU0670â€…PATERNAL USE OF METHOTREXATE AND CONGENITAL MALFORMATIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS. , 2019, , .		0
111	A poison information centre can provide important assessment and guidance regarding medication errors in nursing homes: A prospective cohort study. Basic and Clinical Pharmacology and Toxicology, 2021, 128, 542-549.	2.5	0
112	Mechanisms in Endocrinology: The physiology of neuronostatin. European Journal of Endocrinology, 2021, 185, R93-R101.	3.7	0
113	Topical pharmacological treatment of hemorrhoids during pregnancy and congenital malformations - a nation-wide cohort study. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO3-5-16.	0.0	0
114	Drug use in patients with short bowel syndrome and intestinal failure.. Danish Medical Journal, 2022, 69, .	0.5	0